NCT05129605View on ClinicalTrials.gov

Prostate Cancer Genetic Risk Evaluation and Screening Study

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2040

Conditions
Prostatic NeoplasmProstate CancerBRCA2 MutationBRCA1 MutationATM Gene MutationMMR MutationLynch SyndromeGenetic Predisposition to Disease
Interventions
DIAGNOSTIC_TEST

Prostate cancer screening

Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER